Good morning, everyone. My name is Daryl, and I will be your conference operator today. Thank you for standing by, and welcome to today's joint conference call regarding the LENZ Therapeutics and Graphite Bio proposed merger. At this time, all participants are in a listen-only mode. Please be advised that the call is being recorded. With me on today's call are Graphite Bio CEO, Kim Drapkin, and LENZ Therapeutics CEO, Eef Schimmelpenninck. Before I turn the call over to Kim and Eef, I would like to remind everyone that this discussion will contain forward-looking statements based upon the current expectations of Graphite Bio and LENZ Therapeutics, which include, but are not limited to, statements regarding the expected timing, completion, effects, and potential benefits of the proposed merger transaction, including the concurrent private financing and our future expectations, plans, and prospects for the combined company. Such statements represent management's judgment and intention as of today, and involve assumptions, risks, and uncertainties. Graphite Bio and LENZ Therapeutics undertake no obligation to update or revise any forward-looking statements except as required by law. Further, Graphite Bio intends to file a registration statement and accompanying proxy statement and prospectus with the Securities and Exchange Commission related to the proposed reverse merger. Please be advised to read, when available, the proxy statement and prospectus and other relevant documents filed with the SEC, as these will contain important information about Graphite Bio, LENZ Therapeutics, and the transaction. Once available, these documents can be obtained free of charge from the SEC at sec.gov or on Graphite Bio's website. I would now like to hand the call over to Kim, Kim Drapkin, CEO of Graphite Bio. Thank you, Kim. You may begin. Thank you, and good morning, everyone. This morning, we issued a joint press release announcing the proposed merger between Graphite Bio and LENZ Therapeutics, a privately held, late-stage biopharmaceutical company currently conducting phase 3 trials for its product candidates, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily aceclidine-based eye drops for the treatment of presbyopia. The press release is available on both companies' websites. Following a comprehensive and thoughtful strategic process, we are pleased to be moving forward with LENZ. We believe LENZ is well positioned to create near-term value for shareholders, with its product candidates having positive phase 2 clinical trial results, phase 3 trials reading out in the near term, and the potential to submit a new drug application by the middle of next year. LENZ's team has significant clinical and commercialization experience, and the company is backed by an impressive roster of investors. Before turning the call over to Eef, I would like to thank the entire Graphite Bio team, our advisors, and our partners for their dedication, diligence, and collaboration throughout this process, allowing us to reach this outcome. LENZ's mission to improve vision with its innovative therapies represents a large unmet need and addressable market, and we are confident in LENZ's management team to drive significant long-term value for stakeholders. I will now turn the call over to Eef Schimmelpenninck, CEO of LENZ Therapeutics. Thank you, Kim, and thanks to everyone for joining us on this morning's call. This marks an incredible, transformative, and exciting opportunity for LENZ, providing the combined company with continued support from a strong syndicate of experienced healthcare investors and a strong cash position to robustly support, if approved, commercialization of our presbyopia eye drop. Before I expand more on that, let me take you through the transaction. As outlined in this morning's press release, the proposed merger is an all-stock transaction. In connection with the merger, Graphite Bio has entered into a subscription agreement for a PIPE financing of $53.5 million with a syndicate of healthcare investors led by LENZ's existing investors, with participation from new investors. The PIPE financing is expected to close concurrently with the completion of the merger. Pre-merger Graphite Bio stockholders are expected to own approximately 35% of the combined company, and pre-merger LENZ Therapeutics stockholders are expected to own approximately 65% of the combined company upon the closing of the merger and prior to the additional PIPE financing transaction. The percentages of the combined company that each company's former stockholders are expected to own may be adjusted based on Graphite Bio's net cash at closing. The merger has been unanimously approved by the board of directors of both companies and is expected to close in the first quarter of 2024, subject to customary closing conditions, including the approvals of stockholders of each company. Graphite Bio is expected to contribute approximately $150 million to the combined entity and expects to pay a dividend to Graphite Bio shareholders of approximately $60 million at the close of the transaction. With the anticipated cash on hand at the time of the merger and the private financing closing, the combined company is expected to have approximately $225 million of cash and cash equivalents, which is expected to allow the combined company to continue building infrastructure and successfully commercialize the LENZ presbyopia eye drop following completion of the ongoing phase 3 trials and subject to FDA approval. The combined company will be led by the existing LENZ management team. Turning now to an overview of the company. LENZ is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision. Our initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45. Presbyopia impacts an estimated 1.8 billion people globally and 128 million people in the United States, making it the most prevalent ophthalmology indication outside latent refractive errors. On an addressable population basis, presbyopia is almost 4 times greater than dry eye disease and 3 times greater than childhood myopia, macular degeneration, diabetic retinopathy, and glaucoma combined. Furthermore, the market opportunity for presbyopia is growing due to the aging of the general population, and as people continue working and stay active longer, people with presbyopia will require effective treatment that can enable near vision acuity to continue to function in their daily lives. We believe that a once-daily eye drop that can effectively and safely improve near vision throughout the full workday without impacting business vision, will be a highly attractive commercial product, with an estimated U.S. market opportunity in excess of $3 billion. It is our goal to develop and commercialize the leading eye drop for presbyopia, and we have assembled a team with extensive clinical, commercial, and operational experience to execute this goal and become the category leader. Our team is further supported by a strong group of investors that share our commitment to helping the millions of people with presbyopia in the United States and globally. Our lead candidates, LNZ100 and LNZ101, are aceclidine-based eye drops designed to restore the loss of near vision associated with presbyopia. LNZ100 is a 1.75% ready-to-use formulation of aceclidine. LNZ101 is the same product, but with 0.08% brimonidine added for extended duration. Each product candidate is designed to be a once-daily dose that can provide at least 10 hours of improved near vision. Both product candidates are preservative-free, enabling it to be single use, which is a more convenient delivery method for eye drops for users. I'll go into greater detail on these two product candidates after providing some background on the underlying biology of presbyopia and the unique mechanism of action of aceclidine. As mentioned, there are approximately 1.8 billion presbyopes globally and 128 million presbyopes in the United States alone. It is an inevitable condition that will affect almost all of us at some point. This is because as we age, the crystalline lens in our eyes gradually hardens, resulting in a loss of elasticity that in turn reduces the ability of the lens to focus incoming light for near vision onto the retina. While the progression of presbyopia is gradual, presbyopes often experience an abrupt change in their daily life as the symptoms become more pronounced, starting in their mid-forties, when reading glasses or other corrective aids are suddenly necessary to read text or conduct close-up work. Presbyopia is typically self-diagnosed and self-managed with over-the-counter reading glasses, or managed after evaluation by an eye care professional with prescription reading or bifocal glasses. Aceclidine, a key ingredient in our product candidates, LNZ100 and LNZ101, is a miotic. Miotics are small molecule compounds that cause pupil constriction, creating a pinhole effect that enables better focus of incoming light from near objects onto the retina. Research has shown that a pupil diameter below 2 millimeters is optimal for presbyopia treatment and results in clinically meaningful improvements in near vision. Unlike other miotics, such as pilocarpine and carbachol, aceclidine's mechanism of action is pupil selective, meaning it can reduce the pupil size below the desired 2-millimeter diameter without overstimulating the ciliary muscles that can cause a myopic shift that can impair distance vision. Aceclidine's unique pupil selectivity also means that it does not require activation of the lens to improve near vision. Therefore, we have shown that users may be able to benefit from the treatment with the aceclidine-based eye drops, even as the lens continues to harden as they age and well into their mid-70s and across a broader range of refractive errors. Lastly, while the aceclidine is new to the United States, it has a long-established history outside the United States, having been approved in Europe since the 1970s for the treatment of glaucoma and marketed at higher concentrations than in our product candidates and up to four times a day. Similarly, brimonidine also has a long-established history of use, including as a treatment for glaucoma since the 1990s. Given the known favorable tolerability profile of both active ingredients used for decades in other marketed drugs and the unique pupil selectivity of aceclidine, we believe LNZ100 and LNZ101 have the potential to treat the broadest population of presbyopes and become the category leader. With that, I'd like to briefly recap the design and results of our phase 2 INSIGHT trial, for which we shared top-line data in October 2022. The INSIGHT trial was a multi-center, double-masked, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of LNZ100 and LNZ101. Each participant was monitored, and visual acuity, including impact on distance vision, was measured by a standardized eye test at certain time points. Both LNZ100 and LNZ101 achieved the primary endpoint of three lines or greater improvement in near vision, without losing one or more lines in distance visual acuity at 1 hour post-treatment, with a responder rate of 71% and 56% respectively, compared to 6% per vehicle. Both LNZ100 and LNZ101 showed rapid onset, with response rates of 73% and 62% respectively, compared to 8% for vehicle, for three lines or greater improvement in near visual acuity at 30 minutes post-treatment, the earliest measured time point. Maximum response rates of 73% and 64% respectively, versus 6% for vehicle at 3 hours post-treatment, and a long duration of response, with response rates of 37% and 48% respectively, compared to 4% for vehicle at 10 hours post-treatment, the last measured time point. 94% of the subjects treated with LNZ100 or LNZ101 regained functional near vision with a near visual acuity of 20/40 or better, which would enable them to read the fine print on a sugar packet when none could do so prior to dosing. Both LNZ100 and LNZ101 were well-tolerated, with no serious drug-related adverse events. Importantly, participants also completed a patient-reported outcome questionnaire as part of the trial, and 95% of subjects treated with LNZ100 or LNZ101 reported that they noticed an improvement in near vision following such treatment. 87% indicated that they expected to be less dependent on their reading glasses, and of the 86% who wished to continue to use LNZ100 or 101 at home, 73% indicated that they were likely to use the product at least four times a week. Following the positive outcomes of the INSIGHT trial, we initiated 3 phase 3 multicenter, double-masked, randomized, active, and vehicle-controlled, U.S.-based efficacy and safety trials for LNZ100 and LNZ101 in December 2022. These parallel trials are being conducted across 37 sites and in over 1,000 patients. CLARITY 1 and 2 are evaluating the safety and efficacy of LNZ101 versus LNZ100, versus brimonidine or vehicle over the course of 6 weeks. CLARITY 3 is evaluating the long-term safety of LNZ101 versus LNZ100 over the course of 6 months. The primary endpoints and the study population of the CLARITY trials are similar to that of the INSIGHT trial. We have been enrolling participants in the same age range from 45 to 75 years, and with a similar refractive range of -4 to +1 diopters of spherical equivalent. As with the INSIGHT trial, the CLARITY trials will also permit enrollment of users who have previously undergone prior vision correction, such as LASIK or cataract extraction with lens implants. To date, CLARITY 1 and CLARITY 3 are both fully enrolled, and CLARITY 2 is 95% enrolled. Therefore, and as mentioned earlier, we are on track to report results from all three trials in the second quarter of 2024. Subject to successful completion of the CLARITY trials, we plan to submit a new drug application for at least one of our product candidates to the FDA middle of next year, and we'll select and launch, if approved, the presbyopia eye drop product that we believe will have the greatest commercial potential. Turning now to discuss our robust commercial strategy. Presbyopia is a consumer-driven and cash pay market that requires intense focus on the needs and desires of presbyopes. We believe that the likely demand for a pharmaceutical option is driven by multiple factors, most notably presbyopes seeking to have a functional visual benefit in their day-to-day life, as well as those that want the cosmetic benefit of not requiring reading glasses. From a functional perspective, we expect that users may be able to benefit from treatment from their mid-forties well into their mid-seventies and across a broad range of refractive errors, as demonstrated in clinical testing to date. Therefore, we are focusing on targeting and partnering with both optometry and ophthalmology to enable efficient commercialization and rapid adoption of our product. We are currently educating eye care professionals on the importance of pupil selective miotics that have a clinical profile that reduces pupil diameter below 2 millimeters with minimal ciliary muscle stimulation. If approved, we plan to communicate the efficacy profile of the approved products and highlight the value proposition of an alternative treatment option for presbyopia that would be available to these eye care professionals. In parallel, our commercial team will develop a highly targeted and digitally focused consumer strategy to identify, target, and build loyalty among presbyopes in the United States. We expect to commercialize through the self-pay U.S. healthcare market, which we believe is strategically advantageous and enables immediate patient access and volume-based pricing strategies. Additionally, our product candidates have patent protection until at least 2039, due to a robust intellectual property portfolio underpinned by issued patents. If one of our product candidates is approved, we believe that it could be the first FDA-approved aceclidine-based product and would then be eligible for five years of new chemical entity exclusivity in the United States. To conclude, presbyopia affects almost every person at some point after their mid-forties, representing an enormous market for an effective eye drop, able to restore near vision, and we are well-positioned to be leaders in this space. With rapid responses as early as 30 minutes following use of the eye drop, at least 10 hours duration of response, as shown in our phase 2 trial, we can see LNZ100 or LNZ101, if approved and commercialized, potentially being incorporated into the daily morning routines of millions of people. We are incredibly pleased with the breadth of data collected to date for both of our product candidates, providing us with what we expect will be a robust package supporting the potential approval and commercialization of LNZ100 or LNZ101, assuming positive results for the CLARITY trials. We've built an incredible team with a focus on a strong commercial foundation, and with this transaction, we will be even better positioned for success, with a strong cash position to continue to build the commercial infrastructure to successfully address this multibillion-dollar market and provide an easy, safe, and effective solution for millions of people worldwide. To wrap up, I'd like to thank both the teams at Graphite Bio and LENZ for their collaboration in this merger. We believe that this transformative transaction provides a solid foundation to benefit patients and provide value to stakeholders. Thank you to our syndicate of investors who participated in this financing. And lastly, I would like to thank everyone for your time today. I look forward to keeping you updated on your progress. Thank you. That does conclude today's teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day.